Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Blood (2024) 144 (Supplement 1): 4729.

https://doi.org/10.1182/blood-2024-193583

Published: 2024

Journal Articles

The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans

Yihao Zhan, Hongling Peng, David E. Mery, Eric Siegel, Clyde Bailey, Catherine Ma, Hongwei Xu, Daisy V. Alapat, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 1904.

https://doi.org/10.1182/blood-2024-203848

Published: 2024

Journal Articles

The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease

Mateo Sarmiento Bustamante, Criswell L. M. Lavery, Adam Bagg, Mary Jo Lechowicz, Daisy V. Alapat, Amy Chadburn, Megan S Lim, Gordan Srkalovic, Frits van Rhee, Joshua D Brandstadter, David C. Fajgenbaum

Blood (2024) 144 (Supplement 1): 1156.

https://doi.org/10.1182/blood-2024-211190

Published: 2024

Journal Articles

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

Samer Al Hadidi, Obada Ababneh, Carson W Ercanbrack, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert Smith, Susan Panozzo, Guido Tricot, Daisy V. Alapat, John D Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Maurizio Zangari, Frits van Rhee

Blood (2023) 142 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2023-181034

Published: 2023

Journal Articles

A 5-Stage System for ASCT Multiple Myeloma

Wancheng Guo, David E. Mery, Eric Siegel, Fumou Sun, Yan Cheng, Visanu Wanchai, Cody Ashby, Clyde Bailey, Daisy V. Alapat, Hongling Peng, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 3331.

https://doi.org/10.1182/blood-2023-181117

Published: 2023

Journal Articles

Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma

Carolina Schinke, Leo Rasche, Cody Ashby, Rudy van Hemert, Sharmilan Thanendrarajan, Samer Al Hadidi, Maurizio Zangari, Clyde Bailey, Daisy V. Alapat, John D Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Frits van Rhee, Niels Weinhold

Blood (2023) 142 (Supplement 1): 882.

https://doi.org/10.1182/blood-2023-180896

Published: 2023

Journal Articles

Prognostic Value of Ferritin in ASCT MM Patients: Integration with GEP Models and ISS Series Systems

Wancheng Guo, David E. Mery, Eric Siegel, Fumou Sun, Yan Cheng, Cody Ashby, Daisy V. Alapat, Hongling Peng, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 6573.

https://doi.org/10.1182/blood-2023-181254

Published: 2023

Journal Articles

Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma

Sandra Susanibar, MD, Victoria Carlton, PhD, Sharmilan Thanendrarajan, MD, Meera Mohan, MD, Pankaj Mathur, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Faith E Davies, MD, Katherine A. Kong, PhD, Gareth J Morgan, MD PhD, Daisy V. Alapat, MD, Carolina Schinke, MD

Blood (2016) 128 (22): 377.

https://doi.org/10.1182/blood.V128.22.377.377

Published: 2016

Journal Articles

Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM)

Bruno Paiva, PhD, Sarah K. Johnson, PhD, Maria-Victoria Mateos, MD PhD, Daisy V. Alapat, MD, Noemi Puig, MD PhD, Miguel-T Hernandez, Fernando Escalante, Alfonso Garcia de Coca, MD PhD, Joan Bladé, Juan Jose Lahuerta, Quentin Lecrevisse, Jacques J.M. van Dongen, MD PhD, Alberto Orfao, MD PhD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD, Jesus San Miguel, MD PhD

Blood (2016) 128 (22): 373.

https://doi.org/10.1182/blood.V128.22.373.373

Published: 2016

Journal Articles

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Blood (2016) 128 (22): 2064.

https://doi.org/10.1182/blood.V128.22.2064.2064

Published: 2016

Journal Articles

Overall Outcomes of Bing-Neel Syndrome after Treatment - a Review of 40 Cases

Varinder Kaur, MD, Al-Ola Abdallah, MD, Arjun Swami, MD, Shebli Atrash, Daisy V. Alapat, MD, Zhifu Xiang, MD, Pooja Motwani, MD, Fade Mahmoud, MD, Issam Makhoul, MD, Peter Dean Emanuel, MD

Blood (2015) 126 (23): 5019.

https://doi.org/10.1182/blood.V126.23.5019.5019

Published: 2015

Journal Articles

Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience

Meera Mohan, Rohan Samant, Larry J Suva, Corey O Montgomery, Daisy V. Alapat, MD, Roy Morello, Frits van Rhee, MD PhD, Sarah Waheed, MD, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Christoph Heuck, MD, Yogesh Jethava, MD, Donald Johann, MD MS, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD, Maurizio Zangari, MD

Blood (2015) 126 (23): 4193.

https://doi.org/10.1182/blood.V126.23.4193.4193

Published: 2015

Journal Articles

Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM)

Sharmilan Thanendrarajan, MD, Daisy V. Alapat, MD, Maurizio Zangari, MD, Carolina Schinke, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Adam Rosenthal, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 1843.

https://doi.org/10.1182/blood.V126.23.1843.1843

Published: 2015

Journal Articles

Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma

Blood (2015) 126 (23): 2979.

https://doi.org/10.1182/blood.V126.23.2979.2979

Published: 2015

Journal Articles

Waldenstrom's Macroglobulinemia Associated Bone Disease the UAMS Experience

Xenofon Papanikolaou, MD, Sarah Waheed, MD, Bart Barlogie, MD PhD, Daisy V. Alapat, MD, Donghoon Yoon, PhD, Manoj Kumar, MD, Aasiya Matin, MD, Hongyun Zhu, MD, Cerisse Harcourt, APN, Maurizio Zangari, MD

Blood (2014) 124 (21): 2999.

https://doi.org/10.1182/blood.V124.21.2999.2999

Published: 2014

Journal Articles

Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival

Xenofon Papanikolaou, MD, Qing Zhang, PhD, Christoph Heuck, MD, Sarah Waheed, MD, Shebli Atrash, MD, Zeba N Singh, MD, Daisy V. Alapat, MD, Frits van Rhee, MD, PhD, Shweta S. Chavan, PhD, Joshua Epstein, DSc, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1911.

https://doi.org/10.1182/blood.V122.21.1911.1911

Published: 2013

Journal Articles

Isolated Prolonged Prothrombin Time Correlates with Serum Immunoglobulin Levels in Patients with Multiple Myeloma

Soumya Pandey, MD, Steven R Post, PhD, Daisy V. Alapat, MD, Ginell R. Post, MD, PhD

Blood (2011) 118 (21): 1225.

https://doi.org/10.1182/blood.V118.21.1225.1225

Published: 2011

NARROW

Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans

The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

A 5-Stage System for ASCT Multiple Myeloma

Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma

Prognostic Value of Ferritin in ASCT MM Patients: Integration with GEP Models and ISS Series Systems

Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma

Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM)

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Overall Outcomes of Bing-Neel Syndrome after Treatment - a Review of 40 Cases

Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience

Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM)

Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma

Waldenstrom's Macroglobulinemia Associated Bone Disease the UAMS Experience

Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival

Isolated Prolonged Prothrombin Time Correlates with Serum Immunoglobulin Levels in Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only